Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib

Conditions

• CML-CP; Mutation;Suboptimal Response or Failure in TKI

Interventions

• DRUG: Flumatinib
• DRUG: Nilotinib

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology